Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade B 86.765 -0.50% -0.44
ABBV closed up 1.45 percent on Wednesday, December 4, 2019, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical ABBV trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish -0.50%
Fell Below 20 DMA Bearish 0.95%
1,2,3 Pullback Bullish Bullish Swing Setup 0.95%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.95%
Doji - Bullish? Reversal 0.95%
Down 3 Days in a Row Weakness 0.95%
Gapped Down Weakness 0.95%
NR7 Range Contraction -1.10%
NR7-2 Range Contraction -1.10%
NR7 Range Contraction -1.77%

Older signals for ABBV ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Chemistry Chemical Compounds Organic Compounds Pharmaceutical Products Autoimmune Diseases Prostate Cancer Chloroarenes Cardiology Cholesterol Low Density Lipoprotein Gabaa Receptor Positive Allosteric Modulators Lipoproteins Secondary Hyperparathyroidism Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Research Based Biopharmaceutical Testosterone Replacement Therapy

Is ABBV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 92.99
52 Week Low 62.66
Average Volume 7,508,434
200-Day Moving Average 76.0566
50-Day Moving Average 80.342
20-Day Moving Average 86.7075
10-Day Moving Average 87.148
Average True Range 1.6226
ADX 39.52
+DI 33.3479
-DI 20.5401
Chandelier Exit (Long, 3 ATRs ) 85.5422
Chandelier Exit (Short, 3 ATRs ) 85.21779999999999
Upper Bollinger Band 90.4876
Lower Bollinger Band 82.9274
Percent B (%b) 0.57
BandWidth 8.7192
MACD Line 2.0088
MACD Signal Line 2.5287
MACD Histogram -0.5199
Fundamentals Value
Market Cap 139.01 Billion
Num Shares 1.59 Billion
EPS 4.07
Price-to-Earnings (P/E) Ratio 21.43
Price-to-Sales 5.35
Price-to-Book 23.76
PEG Ratio 1.00
Dividend 2.56
Dividend Yield 2.94%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 89.35
Resistance 3 (R3) 89.22 88.39 88.99
Resistance 2 (R2) 88.39 87.84 88.45 88.87
Resistance 1 (R1) 87.79 87.50 88.09 87.92 88.75
Pivot Point 86.96 86.96 87.11 87.02 86.96
Support 1 (S1) 86.36 86.41 86.66 86.49 85.65
Support 2 (S2) 85.53 86.07 85.59 85.53
Support 3 (S3) 84.93 85.53 85.41
Support 4 (S4) 85.06